Triple-negative breast cancer can't be targeted; chemotherapy is the only option
The old claim turned out to be wrong and was rejected by evidence.
TaughtTriple-negative breast cancer lacks the three receptors that targeted drugs aim at, which is what 'triple-negative' means. With no target to hit, treatment falls back on general chemotherapy, and outcomes are poor.
NowOn 22 May 2026 the FDA approved Datroway (datopotamab deruxtecan), the first targeted therapy to beat chemotherapy on survival in first-line metastatic triple-negative breast cancer. It homes in on a protein called TROP2 and delivers a chemotherapy payload directly to the tumor cells.
What actually happened
The trick is that 'no target' referred to the three classic receptors: estrogen, progesterone, HER2. Datroway ignores those and aims at TROP2, a protein sitting on the surface of most of these tumors. It is an antibody-drug conjugate: an antibody that finds TROP2 carrying a chemotherapy warhead, so the poison is delivered to the cancer rather than the whole body. In the TROPION-Breast02 trial it roughly doubled progression-free survival versus standard chemo and, notably, improved overall survival.
This is for patients who aren't candidates for immunotherapy, and it is a better treatment, not a cure; the disease remains among the hardest in oncology. But the sentence taught for years, that triple-negative disease offers nothing to aim at and leaves only blunt chemotherapy, is now wrong. There is a target, and a drug that hits it.
Newsletter
Get new weekly revisions
Sources
Who was taught this
Still standard through 2026, so anyone who finished school between 1950 and 2026 learned the earlier version.